Tue, 19 Mar 2019RO Ro  EN En    
 
Links
 
 
Project List » 177Lu–Neurotensin – Radipharmaceutical Product for Cancer Targeted Radiotherapy. Neurotensin Agonist and Antagonist Interactions with Peptide Receptors Involved in Radiopharmaceutical and Radiotherapy Evaluation

177Lu–Neurotensin – Radipharmaceutical Product for Cancer Targeted Radiotherapy. Neurotensin Agonist and Antagonist Interactions with Peptide Receptors Involved in Radiopharmaceutical and Radiotherapy Evaluation
proiecte.nipne.ro/pn2/55-projects.html


Acronym: NAGANT
Contracting Authority: Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)
Number / Date of the contract: D41-080 / 14.09.2007
Parteneriate in domeniile prioritare
Project Manager: Diana Chiper
Partners:
Starting date / finishing date: 2007-09-15 / 2010-12-10
Project value: 1479388 RON
Abstract: The NAGANT project is dedicated to high complexity researches and is based on experimental and applicative research aspects in radiochemistry, nuclear physics, biology and nuclear medicine, in order to develop new products and methods in cancer diagnosis, localization, monitoring and targeted therapy. The project is conceived with a modular structure, including:
A. One chemical/radiochemical module – approaching new techniques and methods for radiolabeling of Neurotensin (NT) agonist and antagonist molecules with therapeutic radionuclide 177Lu
B. One biologic module – includes experimental researches on cellular models and animals, normal or bearing tumors that express NT neuroreceptors. In this module will be developed methods for radiolabeled NT in vitro evaluation, regarding its binding to receptors (quantified by IC50 values), 177Lu-NT bond stability (quantified by Kd values), the internalization/externalization degree of the 177Lu-NT in neurotensin receptors, positive expressed cells, study of unlabeled neurotensin blocking effects at tumor cells level, agonist and antagonist effects in the kinetics of radiolabeled neurotensin coupling processes at cell receptors level.
C. One module of applicative research on animal models which includes targeted radiotherapy of neurotensin receptors studies, in presence in absence of neurotensin antagonists. The results of these experiments will led to cancer treatment protocols realization by targeted therapy method. The present project is one of multidisciplinary research that couples chemical, radiochemical and biomolecular researches with scientific contribution to the elucidation of the paradigm regarding neurotensin agonist or antagonist uptake at cell tumor level as well as the elaboration of a new radiopharmaceutical product for cancer diagnosis, imagistic and targeted therapy.

Objectives:

THE STAGES OF THE PROJECT AND DELIVERY DATES
1.  (2007-12-15)
2.  (2008-12-15)
3.  (2009-09-15)
4.  (2009-12-15)
5.  (2010-12-10)
RESULTS
PUBLISHED ARTICLES
RESEARCH TEAM


Back to the Project List
Versiunea proiectului in limba romana RO   
 
Address: Str. Reactorului no.30, P.O.BOX MG-6, Bucharest - Magurele, ROMANIA
Tel: +(4021) 404.23.00, Fax: +(4021) 457.44.40
2019 IFIN-HH. All rights reserved.